$ABT

Abbott Laboratories (ABT) announced a partnership with Berry Street for its Lingo glucose monitor and virtual nutrition coaching. The company also reported first clinical use of its Volt PFA system in Canada and the US. Abbott projects $60.0b revenue and $9.6b earnings by 2029, with 8.8% yearly revenue growth. The partnership and Volt PFA updates support Abbott's long-term narrative, but near-term earnings risks remain due to legal and regulatory exposure in the Nutrition segment.

Abbott Laboratories and Nevro are arguing against consolidating lawsuits over their spinal cord stimulators before the U.S. Judicial Panel on Multidistrict Litigation. Separately, a judge heard objections to a $7.25 billion settlement over Monsanto's Roundup pesticide.

Abbott Laboratories will pay $385M to settle DOJ allegations of unsanitary conditions at two infant formula plants, per whistleblower claims. The DOJ announced the settlement.

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

Abbott Laboratories (ABT) reported higher quarterly revenue than Intuitive Surgical (ISRG) over the last eight quarters, but ISRG grew revenue at a faster pace. ABT's revenue grew 19% from Q3 2024 to Q2 2026, while ISRG's revenue grew 45%. Both companies have steady revenue trajectories. ABT reported a 14% operating margin, ISRG 34%. ABT offers a 2.5% dividend yield.

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

Abbott Laboratories will pay $384 million to resolve claims it sold potentially contaminated baby formula through Medicaid and WIC programs. New York will receive $9.3 million, with $5.3 million going directly to the state. The settlement follows a 2025 lawsuit alleging safety standard violations and misled inspections.

New York Attorney General Letitia James announced a settlement with Abbott Laboratories, where the company will pay over $384 million for alleged safety violations in its baby formula products. Abbott is accused of failing to maintain safety standards from 2018 to 2022, leading to potential contamination and misuse of Medicaid and WIC funds. New York will receive over $9.3 million from the settlement.